Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coverage For Off-Label Cancer Drugs, Genomic Tests Tackled In Policy Report

This article was originally published in The Pink Sheet Daily

Executive Summary

The Green Park Collaborative seeks public comments on recommended guidelines for insurance coverage of tumor profiling through next-generation DNA sequencing and off-label treatment of targeted cancer drugs.

You may also be interested in...



Roche Could Repeat Genentech Success With Foundation Medicine Partnership

Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.

FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE

Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.

Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill

By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel